Symbol Lookup

Thursday April 28, 2016 9:54 PM ET. Data delayed 15 minutes.
11.90
-0.07 (-0.58%)
Bid/Lots
11.91/0
Ask/Lots
11.94/0
Open/Prev Close
11.95/11.97
Day Range
11.46-12.06
52-Week Range
9.20-19.03
Vol/Avg Daily Vol
36.4K/84.8K
  • TSX Comp
  • TSX Venture
  • DJIA
  • S&P 500
  • NASDAQ
Price Comparison Chart
Data delayed at least 15 minutes.

Recent News»

0 New Today
European ADRs Edge Lower in Wednesday Trading
11:44AM ET on Wednesday Apr 20, 2016 by MT Newswires
11:44 AM EDT, 04/20/2016 (MT Newswires) -- American depository receipts of European stocks were trading -0.34% lower at 125.80 on the Bank of New York Mellon Europe ADR Index Wednesday morning. French semiconductor company Sequans Communications ...
European ADRs Move Higher on Strength of Natural Resources, Mining Stocks in Tuesday Trading
12:34PM ET on Tuesday Apr 19, 2016 by MT Newswires
12:34 PM EDT, 04/19/2016 (MT Newswires) -- American depository receipts of European stocks were trading +1.54% higher at 126.08 on the Bank of New York Mellon Europe ADR Index Tuesday morning, bolstered by rising natural resources and mining stoc...
BRIEF-Trinity Biotech reports Q1 earnings of $0.064 per share
9:15AM ET on Tuesday Apr 19, 2016 by Thomson Reuters

April 19 (Reuters) - Trinity Biotech Plc

* Trinity biotech announces results for q1, 2016

* Q1 revenue $23.5 million versus i/b/e/s view $24.2 million

* ...

Trinity Biotech Misses Q1 EPS and Revenue Estimates
9:13AM ET on Tuesday Apr 19, 2016 by MT Newswires
09:13 AM EDT, 04/19/2016 (MT Newswires) -- Trinity Biotech (TRIB) reported Q1 adjusted net income of $700,000, or $0.06 per ADR, missing Wall Street estimates of $0.08 per ADR. For the same quarter last year, the company reported earnings of $0.1...
Trinity Biotech Announces Results for Q1, 2016
8:29AM ET on Tuesday Apr 19, 2016 by GlobeNewswire

Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2016.

Company Information

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Trinity Biotech also is a provider of raw materials to the life sciences and research industries globally. Trinity Biotech markets its portfolio of almost 850 products to customers in approximately 100 countries around the world. The primary market for Trinity Biotech's diagnostic products is the Americas (which consists principally of North America and South America). Its products are classified as point-of-care, emergency medicine, clinical laboratory and blood bank screening. The Company markets products under Uni-Gold, Recombigen, Meritas, Captia, MicroTrak, Bartels, MarDx, MarBlot, Premier, Ultra2, ImmuBlot, ImmuGlo, ImmuLisa, OTOblot and EZ.

CONTACT INFORMATION

HeadquartersIDA Business Park
BRAY, Ireland 18
Phone--
Fax--

EXECUTIVE OFFICERS

Executive Chairman of the BoardRonan O'Caoimh
Chief Financial Officer, SecretaryKevin Tansley
Chief Operating Officer, Executive DirectorRory Nealon
Chief Scientific Officer, and Vice President CardiacEric Brouwer
Executive DirectorJames Walsh

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Stocks Ratings Sample

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

  •  
  • INK Company Insider

    Detailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®

  • S&P Capital IQ Stock Report

    S&P Capital IQ's analysts' overview and valuation, with key fundamental, quantitative, and technical analysis.

  • TDSI Morning Action Notes

    Morning Institutional Report of company updates and new recommendations.

Market Cap$286.8MBeta0.88
Revenue (TTM)$100.2MEPS$0.77
Shares Out.24.0MBook Value$8.93
Dividend Yield1.85%P/E15.6x
Annual Dividend Rate0.22 USDPrice/Sales (TTM)2.9
Ex-Div Date6/5/15P/Cash Flow (TTM)--
Pay Date7/1/15Operating Margin13.42%

*GAAP = prior to non-GAAP analyst adjusted earnings.

(Non-GAAP)*

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Stocks Calendar Sample